Toujours une opportunité d’ACHAT - ACHAT - OC 10,3€
Suite à l’annonce du DSMB recommandant l’arrêt d’un bras de l’étude EFFIKIR évaluant lirilumab en monothérapie dans la LAM, le cours s’est déprécié de 12%. Malgré un décalage de 6 mois sur les résultats prévus dans cette indication, notre thèse d’investissement est maintenue. Sous l’égide de son partenariat avec BMS nous voyons la combinaison lirilumab / anti PD1 comme une véritable opportunité pour laquelle nous restons pourtant extrêmement prudents en appliquant une probabilité de succès de seulement 10%. Avec des premiers résultats qui pourraient être publiés en cette fin d’année, nous maintenons notre recommandation à ACHAT avec un objectif deInnate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.